Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.
Morningstar's Damien Conover discusses the prospects for J&J's stent and drug pipelines.
Morningstar's Josh Peters on considering yield and growth when looking for dividend-stock opportunities.
Bonds may have done well over the last decade but dividend paying stocks like J&J may be the best bet for the next ten years says Morningstar's Josh Peters.
A 36-year-old IT executive crafts a plan for fulfilling his financial ambitions.
©2012 Morningstar Advisor. All right reserved.